First Western Capital Management Co Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : First Western Capital Management Co reduced its stake in Celgene Corporation by 20.58% during the most recent quarter end. The investment management company now holds a total of 55,981 shares of Celgene Corporation which is valued at $6,187,020 after selling 14,505 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Celgene Corporation makes up approximately 2.16% of First Western Capital Management Co’s portfolio.

Celgene Corporation opened for trading at $110.34 and hit $111.5 on the upside on Friday, eventually ending the session at $110.52, with a gain of 0.55% or 0.6 points. The heightened volatility saw the trading volume jump to 48,55,538 shares. Company has a market cap of $86,390 M.

Other Hedge Funds, Including , Magee Thomson Investment Partners reduced its stake in CELG by selling 2,450 shares or 1.9% in the most recent quarter. The Hedge Fund company now holds 126,330 shares of CELG which is valued at $13,961,992. Celgene Corporation makes up approx 4.26% of Magee Thomson Investment Partners’s portfolio. Quantres Asset Management Ltd sold out all of its stake in CELG during the most recent quarter. The investment firm sold 15,500 shares of CELG which is valued $1,713,060. Piershale Financial Group added CELG to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $10,734. Celgene Corporation makes up approx 0.01% of Piershale Financial Group’s portfolio.Oakwood Capital Managementca boosted its stake in CELG in the latest quarter, The investment management firm added 2,030 additional shares and now holds a total of 48,051 shares of Celgene Corporation which is valued at $5,157,794. Celgene Corporation makes up approx 1.35% of Oakwood Capital Managementca’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.